Why the primary cancer record is the starting point, not the brain scan
A brain metastasis is cancer that started elsewhere and spread to the brain. The scan may show where the lesions sit, their size and whether they cause swelling or pressure, but it does not reliably tell the treating team what the original cancer is, how it behaves, or which treatments are likely to help. That information lives in the primary cancer records: the original pathology report, the staging notes, the operation or biopsy summary, and any molecular or receptor testing done on the primary tumour or a metastasis.
This matters for an overseas enquiry because a Chinese hospital reviewing the case will want to know whether the diagnosis is confirmed and what has already been tried. If the primary cancer is unclear, the team may need to request the original pathology slides or blocks for review before it can comment on suitability. That is not a delay tactic; it is how a records-based opinion avoids building on an incomplete picture.
The practical action is to locate the primary cancer pathology report first, then the brain imaging and any brain treatment records. If the primary pathology was done at another hospital, ask that hospital what it can release and in what format. A short summary of the timeline is useful, but the underlying reports are what a specialist reads.
What the report should say about the primary cancer and its markers
The diagnosis report should state the primary cancer type in specific terms, not just 'carcinoma' or 'malignancy'. It should record the site of origin, the histological subtype, the grade if given, and the date of diagnosis. For many cancers that spread to the brain, receptor status or molecular findings change the treatment conversation: for example, hormone receptor and HER2 status in breast cancer, EGFR or ALK alterations in lung cancer, or BRAF status in melanoma. These are not details a patient can infer from a scan.
The report should also clarify whether the molecular testing was done on the primary tumour, a lymph node, or a brain lesion, and when. A result from an old sample may not reflect the current disease. If no molecular testing has been done, that is itself a useful fact for the receiving team to know, because it may affect what they recommend next.
A common gap is a report that lists the primary diagnosis but omits the staging or the treatment history. Staging tells the team how far the disease had spread before the brain lesions appeared. Treatment history tells them what the cancer has already been exposed to. Both shape whether a new option is reasonable or already exhausted.
Previous brain treatment: what to document and why it changes the question
The diagnosis report should clarify whether the brain lesions have already been treated, and if so, how. That includes surgery, whole-brain radiotherapy, stereotactic radiosurgery, or any systemic therapy given with the intention of reaching the brain. The dates, the treated areas, and the response or lack of response all matter. A lesion that has already received maximum radiation may not be suitable for further radiation to the same area, while a new lesion elsewhere may be assessed differently.
The report should also note whether the patient is currently on steroids or anti-seizure medication, and whether there are symptoms such as headaches, seizures, weakness or changes in speech or vision. These details help the receiving team understand urgency and the safety of any travel or treatment planning. They do not replace a local clinical assessment, especially if symptoms are worsening.
If previous brain treatment was given at a different hospital, the treatment summary and the radiation plan or operative note are more useful than a patient's recollection. Ask the treating centre what it can provide. If some records are unavailable, say so clearly in the enquiry rather than leaving the team to assume nothing was done.
Local and systemic care: separating what is urgent from what can be reviewed
Brain metastases care usually involves two parallel tracks: local treatment to the brain, such as surgery or radiotherapy, and systemic treatment for the cancer as a whole, such as targeted therapy, chemotherapy or immunotherapy. The diagnosis report should clarify what is happening on both tracks, because a decision about one affects the other. A patient who is stable on a systemic therapy that controls the disease outside the brain may have a different set of options from someone whose cancer is progressing everywhere.
The report should state the current systemic treatment, the date it started, and the most recent assessment of response. It should also note any significant side effects or organ function problems that could limit treatment. These are the details a specialist uses to judge whether a new approach is safe and reasonable.
If the patient has new or worsening neurological symptoms, that is a reason to seek local urgent care first, not to wait for an overseas review. An overseas enquiry can run alongside local care, but it should not replace it. The receiving team will also want to know who is currently responsible for the patient's care and how to reach them if clarification is needed.
What a records-based review can and cannot tell you about China care
A records-based review can tell you whether the case appears suitable for a specialist appointment, what additional records are missing, and which type of department or team is relevant. It cannot confirm hospital acceptance, final treatment eligibility, or a clinical outcome. Those decisions belong to the treating hospital and its clinicians after they have seen the patient and the full records.
For brain metastases, the relevant team may involve neurosurgery, radiation oncology, medical oncology, or a combination. A multidisciplinary review can be useful when the case crosses specialties, but the scope and fee should be agreed before it starts. The review does not guarantee that a particular treatment is available in China, and it does not replace the hospital's own assessment.
If radiotherapy is part of the discussion, the technique and schedule depend on the individual treatment plan. The diagnosis report should give the receiving team enough to understand what has already been delivered and what remains possible. It should not be used to self-direct radiation decisions. Those require a radiation oncologist's assessment of the actual images and history.
How to prepare the diagnosis report for an enquiry
Start with a one-page summary in English that lists the primary cancer diagnosis and date, the receptor or molecular results, the date and method of brain metastasis diagnosis, previous brain treatment, current systemic treatment, and the patient's main question. Then attach the supporting reports in a logical order: pathology first, then imaging reports, then treatment summaries, then the most recent clinic note. Do not send passport numbers, payment details or a complete archive at the first contact.
Ask the receiving team what format it prefers and whether it needs pathology slides or blocks for review. If the primary pathology was done outside China, the hospital may ask for re-review; that is a clinical decision, not a routine step you can assume. Confirm what the hospital requires rather than sending everything at once.
A brief initial enquiry is free and does not require buying a proxy consultation. The team can check what is available, identify missing records, and suggest a relevant next step. If a proxy consultation or multidisciplinary review is appropriate, the scope and fee are agreed separately, and hospital medical fees remain separate from coordination fees.
The next step is to gather the primary cancer pathology report, the brain imaging reports, and the previous brain treatment summary, then send a short summary through the enquiry form. If symptoms are worsening, seek local care first and treat the overseas enquiry as a parallel planning step.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.